Benjamin Tan, MD

Medical Oncologist

Benjamin Tan

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Expertise & Training

Clinical Expertise

  • Gastrointestinal cancer

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Medical Oncology, WashU Medicine

Board Certification

  • 1997: American Board of Internal Medicine, Medical Oncology
  • 1996: American Board of Internal Medicine, Internal Medicine

Training

  • 1991-1994: Resident, Internal Medicine, Sinai Hospital, Baltimore, MD
  • 1994-1997: Clinical Fellow, Hematology and Medical Oncology, WashU Medicine, St. Louis, MO
  • 1997-1998: Research Fellow, Hematology and Medical Oncology, WashU Medicine, St. Louis, MO

Education

  • 1990: MD, University of the Philippines, Manila, Philippines

Research & Selected Publications

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial
Authors:

Zhang GQ, Meyerhardt JA, Shi Q, one or more additional authors omitted Tan B, one or more additional authors omitted Nowak JA

Journal & Year:

JAMA Oncol | 2026

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma
Authors:

Meyer T, Finn RS, Borad M, one or more additional authors omitted Tan BR, one or more additional authors omitted Sangro B

Journal & Year:

J Hepatol | 2026

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Authors:

Grierson PM, Wolf C, Suresh R, one or more additional authors omitted Tan BR, one or more additional authors omitted Lim KH

Journal & Year:

Clin Cancer Res | 2025

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial
Authors:

Raghav KPS, Guthrie KA, Tan B, one or more additional authors omitted Philip PA

Journal & Year:

J Clin Oncol | 2025

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Authors:

Shroff RT, King G, Colby S, one or more additional authors omitted Tan B, one or more additional authors omitted Philip PA

Journal & Year:

J Clin Oncol | 2025

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Authors:

Nowak JA, Twombly T, Ma C, one or more additional authors omitted Tan B, one or more additional authors omitted Meyerhardt JA

Journal & Year:

J Clin Oncol | 2024

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Authors:

Oh DY, He AR, Bouattour M, one or more additional authors omitted Tan B, one or more additional authors omitted Valle JW

Journal & Year:

Lancet Gastroenterol Hepatol | 2024

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Authors:

Patel SP, Othus M, Chae YK, one or more additional authors omitted Tan B, one or more additional authors omitted Kurzrock R

Journal & Year:

J Immunother Cancer | 2024